Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.

Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. We conducted a multicenter, double-blind, phase 3 ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General ...

Please provide your email address to receive an email when new articles are posted on . Benralizumab induces depletion of eosinophils and mepolizumab reduces activation. The study followed ...

People taking benralizumab were significantly less likely to need further treatment for their asthma or COPD symptoms, a major clinical trial has shown ...

(RTTNews) - Researchers at King's College London have found a new treatment for asthma attacks, which could be a "game-changer" for the patients. Lead investigator Prof Mona Bafadhel, of King's ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

After three months of treatment, four times fewer people taking benralizumab had suffered an asthma or COPD attack, compared to people taking the steroid prednisolone. “This could be a game ...

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...